Email this article Epidemiological features of hepatitis B in the Russian Arctic
- Authors: Fomicheva A.A.1, Pimenov N.N.1, Komarova S.V.1, Urtikov A.V.1, Paevskaya O.A.2, Tsapkova N.N.2, Chulanov V.P.1,2
-
Affiliations:
- National Medical Research Center of Phthisiopulmonology and Infectious Diseases
- The First Sechenov Moscow State Medical University (Sechenov University)
- Issue: Vol 25, No 6 (2020)
- Pages: 253-263
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/1560-9529/article/view/79692
- DOI: https://doi.org/10.17816/EID79692
- ID: 79692
Cite item
Full Text
Abstract
BACKGROUND: Hepatitis B is an urgent medical and social problem in Russia.
AIM: To determine the epidemiological features of the hepatitis B in the Russian Arctic.
MATERIALS AND METHODS: We carried out a retrospective analysis of the incidence of hepatitis B (acute and chronic forms) in 9 Russian Arctic regions, 3 subarctic regions (Khanty-Mansiysk Autonomous Okrug, Magadan Region, Kamchatka Territory) and Russian Federation in 1999–2019. We also studied the prevalence of chronic hepatitis B and vaccination data against hepatitis B in these territories.
RESULTS: From 1999 to 2019 the incidence of acute hepatitis B in three subarctic regions decreased 166 times (from 66.5 to 0.4 per 100 thousand population), in the Arctic zone of 74.5 times (from 29.8 to 0.4 per 100 thousand population) and 73 times in Russia (from 43.8 to 0.6). The incidence of chronic hepatitis forms in the same period in the Arctic zone decreased by 8.6 times (from 140.1 to 16.3), 5.8 times in the subarctic regions (from 116.6 to 20.0) and 5.7 times in Russia (from 96.3 to 16.8). In 2018, the results of the prevalence of chronic hepatitis B in the Arctic zone (697.3) was higher than in Russia by 98% (352.1) and higher in the subarctic regions by 67% (588.6). Timely coverage of hepatitis vaccination in children aged 12 months in the Russian Federation, the Arctic zone and the subarctic regions is maintained at a high level (more than 90%) from 2004 in 2019. Coverage of children by vaccination to 17 years inclusive and adults up to 35 years on these territories also exceeded 90%.
CONCLUSIONS: Vaccination against hepatitis B in the Russian Federation led to a significant decrease in the incidence of this infection in the Russian Arctic. High prevalence of infection indicates the need to continue the program of mass vaccination and the timely introduction of the first dose of vaccine newborns. To reduce the risk of cirrhosis and liver cancer, it is necessary to increase the availability of diagnosis of the disease and its possible outcomes in the Arctic regions and timely provision of antiviral treatment of all patients.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Anastasia A. Fomicheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Email: anastasia.fomichova@yandex.ru
ORCID iD: 0000-0002-0625-0284
SPIN-code: 5281-1670
MD, Junior Research Associate
Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, MoscowNikolay N. Pimenov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Email: n.pimenov@mail.ru
ORCID iD: 0000-0002-6138-4330
SPIN-code: 2314-2076
MD, Cand. Sci. (Med.)
Russian Federation, MD, Junior Research AssociateSvetlana V. Komarova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Email: komarova.056@yandex.ru
ORCID iD: 0000-0002-7681-5455
SPIN-code: 2810-3381
MD, Research Associate
Russian Federation, MD, Junior Research AssociateAleksandr V. Urtikov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Email: urtikovav@mail.ru
ORCID iD: 0000-0001-7319-0712
SPIN-code: 7260-6505
MD, Research Associate
Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, MoscowOlga A. Paevskaya
The First Sechenov Moscow State Medical University (Sechenov University)
Email: paevskaya_o_a@staff.sechenov.ru
ORCID iD: 0000-0003-4917-3992
SPIN-code: 7410-3130
MD, Cand. Sci. (Med.), Assistant Lecturer
Russian Federation, MoscowNatalya N. Tsapkova
The First Sechenov Moscow State Medical University (Sechenov University)
Email: tsapkova.natali@yandex.ru
ORCID iD: 0000-0002-7823-9287
SPIN-code: 3734-7392
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, MoscowVladimir P. Chulanov
National Medical Research Center of Phthisiopulmonology and Infectious Diseases; The First Sechenov Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: ChulanovVP@nmrc.ru
ORCID iD: 0000-0001-6303-9293
SPIN-code: 2336-4545
MD, Dr. Sci. (Med.), Professor
Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, Moscow; MoscowReferences
- Lukin YF. Status, composition, population of the Russian Arctic. Arctic and North. 2014;(15):57–94. (In Russ).
- Fauzer VV, Smirnov AV. The world's arctic: natural resources, population distribution, economics. Arctic: Ecology and Economy. 2018;3(31):6–22. doi: 10.25283/2223-4594-2018-3-6-22
- Bruce M, Zulz T, Koch A. Surveillance of infectious diseases in the Arctic. Public Health. 2016;137:5–12. doi: 10.1016/j.puhe.2016.06.014
- Petrova PG, Borisova NV, Platonov FA, Turkebaeva LK. The role of field research in the study of public health in the Arctic. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2017;(2):4. (In Russ).
- Volova LU, Rodina EV. HIV epidemic situation among Small Indigenous Populations of Northeast Russia. J Infectology. 2014; 6(2):76–82. (In Russ).
- Toropushina EE. Estimation of the social in frastructure development in the North and the Arctic of Russia. EKO. 2016; (6):99–108. (In Russ).
- Zalyalov BA, Pimenov NN, Komarova SV, et al. Epidemiological features of hepatitis B and C in the Arctic Region. Epidemiology and Infectious Diseases. Current Items. 2019;9(1):81–92. (In Russ). doi: 10.18565/epidem.2019.1.81-92
- Petrova DP, Mindlina AY. Comparative analysis of the morbidity of respiratory infections in the Arctic Zone and other Territories of Russia. Epidemiology and Vaccinal Prevention. 2020;19(4): 48–56. (In Russ). doi: 10.31631/2073-3046-2020-19-4-48-56
- Osiowy C, Simons BC, Rempel JD. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic. Antivir Ther. 2013;18(3 Pt B):467–473. doi: 10.3851/IMP2597
- Sleptsova SS. Parenteral viral hepatitis and their outcomes in the Republic of Sakha (Yakutia). Moscow: Chekhovskii Pechatnyi Dvor; 2017. 216 р. (In Russ).
- Semenov SI, Savvin RG, Krivoshapkin VG, et al. Epidemiological characteristics of hepatitis with parenteral transmission mechanism of pathogens in Yakutia. Far Eastern Journal of Infectious Pathology. 2004;(5):20–23. (In Russ).
- Ohba K, Mizokami M, Kato T, et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Epidemiol Infect. 1999;122(1):139–143. doi: 10.1017/s0950268898001940
- Bugaeva TT, Alexeeva MN, Ivanov PM, et al. The chronic viral hepatitis as main risk factors of hepatocellular carcinoma development in Yakutia. Siberian Medical J. 2007;22(S2):47–49. (In Russ).
- McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–807. doi: 10.1002/hep.24442
- Mereckiene J, Cotter S, Lopalco P, et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: Where we were in 2009? Vaccine. 2010;28(28):4470–4477. doi: 10.1016/j.vaccine.2010.04.037
- FitzSimons D, McMahon B, Hendrickx G, et al. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March, 2012. Int J Circumpolar Health. 2013;72:21163. doi: 10.3402/ijch.v72i0.21163
- Børresen ML, Koch A, Biggar RJ, et al. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health. 2012;102(2):277–284. doi: 10.2105/ajph.2011.300239
- WHO. Weekly epidemiological bulletin. July 7, 2017, 92nd year, N 27, 2017, 92, 369–392. Hepatitis B vaccines: WHO position paper, July 2017 [Internet]. Available from: https://www.who.int/wer/2017/pp_hepb_2017_ru.pdf. Accessed: 09.06.2021.
- Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38(3): 257–265. doi: 10.1016/s0168-8278(02)00413-0
- Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95(2):331–339. doi: 10.1002/cncr.10662
- Kershengoltz BM, Chernobrovkina TV, Kolosova ON. Ethnogenetic features of alcohol resistance in the people of the North. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2012;9(1):22–28. (In Russ).
- Chulanov VP. Epidemiological and clinical significance of genetic heterogeneity of hepatitis A and B viruses [dissertation abstract]. Moscow; 2013. (In Russ). Available from: https://www.crie.ru/pdf/avtoref1(chulanov).pdf.
- Zotova AV, Juman AA, Tsikina MN. Significance of viral load determination in hepatits B and C in relatively closed populations of ethnic minorities. The Far Eastern J Infectious Pathology. 2010;16(16):23–26. (In Russ).
- Gounder PP, Bulkow LR, Snowball M, et al. Hepatocellular carcinoma risk in Alaska native children and young adults with hepatitis B virus: retrospective cohort analysis. J Pediatr. 2016;178:206–213. doi: 10.1016/j.jpeds.2016.08.017
- Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5–11. doi: 10.1086/509894
- McMahon BJ, Nolen S, Snowball M, et al. Hepatitis B Virus (HBV) genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for hepatocellular carcinoma: the hepatitis B Alaska (HEP-B-AK) study. Hepatology. 2021. doi: 10.1002/hep.32065
Supplementary files
